Skip to main content

ObsEva SA (OBSV)

NASDAQ: OBSV · IEX Real-Time Price · USD
2.23
-0.01 (-0.45%)
At close: Nov 29, 2021 4:00 PM
2.22
-0.01 (-0.45%)
After-hours:Nov 29, 2021 6:18 PM EST

Company Description

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.

The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization.

The company was founded in 2012 and is headquartered in Geneva, Switzerland.

ObsEva SA
ObsEva Logo
CountrySwitzerland
Founded2012
IPO DateJan 26, 2017
IndustryBiotechnology
SectorHealth Care
Employees42
CEOErnest Loumaye

Contact Details

Address:
Chemin des Aulx 12
Plan Les Ouates, Geneve 1228
Switzerland
Phone41 22 552 38 40
Websiteobseva.com

Stock Details

Ticker SymbolOBSV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001685316

Key Executives

NamePosition
Brian O'CallaghanChief Executive Officer and Director
Dr. Ernest LoumayeCo-Founder and Director
David Renas J.D.Chief Financial Officer
Dr. Jean-Pierre Gotteland Ph.D.Chief Scientific Officer and Head of Research & Development
Fabien Lefebvre de LadonchampsChief Administrative Officer
Mario Vincent CorsoSenior Director of Investor Relations
Delphine RenaudPersonal Assistant to the CSO and Head of Research & Development
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H.Chief Medical Officer
Clive BertramChief Commercial Officer
Luigi MarroChief Transformation Officer

Latest SEC Filings

DateTypeTitle
Nov 23, 2021424B7Prospectus [Rule 424(b)(7)]
Nov 23, 2021EFFECTNotice of Effectiveness
Nov 22, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 10, 2021F-3Registration statement by foreign private issuers
Nov 4, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 29, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 13, 20216-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 13, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 5, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 27, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings